WAVE Life Sciences Ltd WVE-N531 Clinical Trial Update Call Transcript
Good morning, and welcome to the Wave Life Sciences WVE-N531 proof-of-concept clinical trial conference call. (Operator Instructions) As a reminder, this call is being recorded and webcast.
I'll now turn the call over to Kate Rausch, Investor Relations at Wave Life Sciences. Please go ahead.
Thank you, operator. Good morning, and thank you for joining us today. I will be covering for Kate Rausch, while she's out on maternity leave. This morning, we issued a new release, providing an update on the initial cohort of our Phase Ib/IIa proof-of-concept clinical trial evaluating N531 as a potential treatment for Duchenne muscular dystrophy. A slide presentation to accompany this webcast is available at the Investor Relations section of our website at www.wavelifesciences.com. A replay will also be available on the website following today's call.
Before we begin, I would like to remind you that discussions during this conference call will include
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |